ClinicalTrials.gg
RecruitingNCT05761106Updated Mar 6, 2024

Effect of Exercises on Convergence Insufficiency in Individuals With Temporomandibular Disorders

An interventional study of Oculomotor Therapy and Therapy for Temporomandibular Disorder in Temporomandibular Disorder, Temporomandibular Joint Disorders and Temporomandibular Joint Dysfunction Syndrome, sponsored by University of Nove de Julho. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Primary conditionTemporomandibular Joint Dysfunction SyndromeRegistry: Temporomandibular Joint DisordersReclassifiedWhy we changed it
Registry
Temporomandibular Joint Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Temporomandibular Joint Dysfunction Syndrome
Why
  1. The study's listed conditions name Temporomandibular Joint Dysfunction Syndrome, a narrower term within Temporomandibular Joint Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Temporomandibular Disorder is a disorder that involves the muscles of mastication, the temporomandibular joint (TMJ), and associated structures. Convergence insufficiency (CI) is characterized by the inability of the eyes to perform the eye adduction movement together, to focus on a nearby object. Studies show that there is a relationship between the presence of TMD and its signs and symptoms in patients with convergence insufficiency. Given this, the research question of this clinical trial is whether the effect of oculomotor therapy would be effective in improving the signs and symptoms of Temporomandibular Disorder. The design of this research is a Clinical Trial, Randomized and Blind. It will be divided into two moments: evaluation and intervention. The evaluations will be carried out using the Diagnostic Criteria for Temporomandibular Disorders: Fonseca Anamnestic Index (IAF), Clinical Protocol and Assessment Instruments (DC/TMD), Mandibular function Impairment Questionnaire (MFIQ), Numerical Pain Scale (END), Convergence Test, Meersseman Test and Convergence insufficiency symptom Survey (CISS). Individuals will be randomized into 2 groups: Group A (Treatment for Temporomandibular Disorder) and Group B (Treatment Oculomotor plus Treatment for Temporomandibular Disorder). Both groups will receive physiotherapeutic treatment for 12 weeks. Patients will be reassessed shortly after treatment, 3 and 6 months later. For data analysis, the statistical significance considered will be p\<0.05.

02

Conditions studied

  • Temporomandibular Disorder
  • Temporomandibular Joint Disorders
  • Temporomandibular Joint Dysfunction Syndrome
  • Convergence Insufficiency

Keywords

  • Convergence Insufficiency
  • Temporomandibular Disorder
  • Clinical trials
  • oculomotor therapy
  • Physiotherapy
03

In context

Temporomandibular Joint Dysfunction Syndrome Reclassified

54 studies on the registry are indexed under Temporomandibular Joint Dysfunction Syndrome; 14 are open to participants now.

This study's planned enrollment of 24 is below the median of 49 across 43 interventional studies indexed under Temporomandibular Joint Dysfunction Syndrome.

Browse Temporomandibular Joint Dysfunction Syndrome studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Compared within Temporomandibular Joint Dysfunction Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Temporomandibular Joint Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60 years;
  • Presence of pain in the facial region in the last 6 months;
  • Presence of pain, at least 3 on the numeric pain scale (END), in the Temporomandibular Joint and/or masticatory muscles and in the last 6 months;
  • Diagnosis of myogenic Temporomandibular Disorder, by DC/TMD;
  • Moderate and Severe Temporomandibular Disorder carrier, according to Fonseca's Anamnestic Index;
  • Presence of Insufficiency of Convergence according to Convergence Test (TC) and by Convergence insufficiency symptom Survey (CISS).

Exclusion criteria

Exclusion Criteria:

  • Permanent strabismus;
  • History of strabismus surgery;
  • History of cervical and/or craniofacial trauma/surgical procedure;
  • History of ocular nerve injury;
  • Neurological disorders;
  • disc disease ;
  • Systemic diseases;
  • Fibromyalgia diagnosis;
  • Previous treatments for TMD carried out in the last 3 months;
  • Previous treatments of Convergence Insufficiency with oculomotor therapy (no more than 2 months of treatment in the last year);
  • Occlusal treatment in progress;
  • Any ocular or systemic medication known to affect accommodation or vergence ;
  • Systemic diseases that affect ocular accommodation, vergence , and motility, such as multiple sclerosis, Graves' thyroid disease, myasthenia gravis, diabetes, and Parkinson's disease;
  • In continuous use of analgesics, anti-inflammatories, anxiolytics and/or antidepressants;
  • Pregnant women.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Oculomotor Therapy

    The procedures for oculomotor therapy will be arranged sequentially, from easiest to most difficult. It will consist of a convergence technique (Brock Cord and Barrille Cartouche) and an accommodative technique (Eccentric circles or lifesaving cards) and Eye Relaxation.

    Other: Oculomotor Therapy

  • Active comparator
    Therapy for Temporomandibular Disorder

    Extra-oral and intra-oral massage: The main objective is to reduce pain as well as re-establish proper muscle length and flexibility. The patient will be instructed to use diaphragmatic breathing to promote relaxation during these massage procedures. Myofascial release of the masseter, temporalis and sternocleidomastoid muscles, release of neck soft tissues, cervical pomp, suboccipital inhibition, passive anteroposterior mobilization of the upper cervical, cervical exercises, Temporomandibular Joint exercises (mouth opening exercise with tongue on palate) , Proprioceptive exercises).

    Other: Oculomotor Therapy · Other: Therapy for Temporomandibular Disorder

Interventions

  • OtherOculomotor Therapy

    It will consist exercise of a convergence technique and an accommodative technique.

  • OtherTherapy for Temporomandibular Disorder

    It will consist exercise of a ATM and cervical spine.

06

What researchers measure

Primary outcomes

  1. Score in Numerical Pain Scale

    intensity of pain

    Time frame: The level of pain at 12 weeks

  2. Score in Numerical Pain Scale

    intensity of pain

    Time frame: The level of pain at 3 months

Secondary outcomes

  1. measure range of motion

    range of motion

    Time frame: The range of motionat 12 weeks

  2. measure range of motion

    range of motion

    Time frame: The range of motion at 3 months

07

Study locations

1 of 1 sites recruiting
  • Daniela Aparecida Biasotto Gonzalez
    Mogi das Cruzes, SP 08771-910, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The data is confi dential, but if any journal requests open data for publication for sure we will provide our database

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 24 interventional studies with no phase under Temporomandibular Joint Dysfunction Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05761106
Responsible party
Daniela Ap. Biasotto-Gonzalez (Clinical Professor, University of Nove de Julho) — Principal investigator
First posted
Mar 9, 2023
Start date
Feb 1, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion